Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Slack

Showing results (461-470 of 472) with videos related to

Pageof 48
Sort By:
Cell Chemical Biology|September 26, 2023
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapyHaisheng Yu, Jing Liu, Xia Bu, et al.
The European Respiratory Journal|November 20, 2020
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosisNikhil Hirani, Alison C MacKinnon, Lisa Nicol, et al.
European Journal of Pharmacology|November 11, 2021
Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic diseaseAlex L Wilkinson, Alison E John, John W Barrett, et al.
Respiratory Research|March 29, 2020
A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitorToby M Maher, Juliet K Simpson, Joanna C Porter, et al.
The Science of the Total Environment|November 2, 2010
Priority water research questions as determined by UK practitioners and policy makersL E Brown, G Mitchell, J Holden, et al.
Journal of Medicinal Chemistry|February 16, 2013
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonistsPanayiotis A Procopiou, John W Barrett, Nicholas P Barton, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Nature Communications|December 22, 2021
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerNeha Singh, Varune R Ramnarine, Jin H Song, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.
Nature Communications|September 17, 2020
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosisAlison E John, Rebecca H Graves, K Tao Pun, et al.
Pageof 48

Showing results (461-470 of 472) with videos related to

Sort By:
Pageof 48
Cell Chemical Biology|September 26, 2023
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapyHaisheng Yu, Jing Liu, Xia Bu, et al.
The European Respiratory Journal|November 20, 2020
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosisNikhil Hirani, Alison C MacKinnon, Lisa Nicol, et al.
European Journal of Pharmacology|November 11, 2021
Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic diseaseAlex L Wilkinson, Alison E John, John W Barrett, et al.
Respiratory Research|March 29, 2020
A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitorToby M Maher, Juliet K Simpson, Joanna C Porter, et al.
The Science of the Total Environment|November 2, 2010
Priority water research questions as determined by UK practitioners and policy makersL E Brown, G Mitchell, J Holden, et al.
Journal of Medicinal Chemistry|February 16, 2013
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonistsPanayiotis A Procopiou, John W Barrett, Nicholas P Barton, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Nature Communications|December 22, 2021
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerNeha Singh, Varune R Ramnarine, Jin H Song, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.
Nature Communications|September 17, 2020
Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosisAlison E John, Rebecca H Graves, K Tao Pun, et al.
Pageof 48